Drug
Ipn01194
Ipn01194: highest development phase Phase 1/2, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| IPN01194 NCT06305247 | Phase 1/2 | Melanoma |
Latest
No recent events.
Follow Ipn01194 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.